Bank7 Corp. announces $8.35 million quarterly profit
Bank7 Corp. (NASDAQ:BSVN) reported second-quarter 2026 net income of $8.35 million, compared to $11.11 million in the same period last year.
Bank7 Corp. (NASDAQ:BSVN) reported second-quarter 2026 net income of $8.35 million, compared to $11.11 million in the same period last year.
IQSTEL (NASDAQ:IQST) reported $207 million in preliminary first-half net revenue to demonstrate its ongoing 59 percent year-over-year growth.
Greenwich LifeSciences (NASDAQ:GLSI) said European regulators approved combined HLA enrollment across approximately 170–180 FLAMINGO-01 clinical sites.
Medicus Pharma (NASDAQ:MDCX) received central IRB approval and written FDA feedback for its optimized Phase 2 ANT-2111-02 clinical study.
Gibraltar Industries (NASDAQ:ROCK) completed a two-step divestiture of its Renewables business by selling its racking and foundations operations to Unirac.
Abbott (NYSE:ABT) reported second-quarter 2026 sales of $12.6 billion and an adjusted earnings of $1.31 per diluted share.
ManpowerGroup (NYSE:MAN) reported second-quarter 2026 revenues of $4.9 billion and net earnings of $53.5 million.
LCNB Corp. (NASDAQ:LCNB) reported a record second-quarter net income of $7.5 million and earnings of $0.53 per share for the three months ended June 30.
Moderna (NASDAQ:MRNA) dosed the first U.S. participant in its Phase 1 trial evaluating the mRNA-4200 cancer antigen therapy.
Main Street Capital (NYSE:MAIN) projected second-quarter distributable net investment income between $1.02 and $1.06 per share.
GARANTA JÁ SEU GRAFA EDGE
Sign up free to unlock this feature
Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas